Conjugation with a mAb against death receptor-5 (DR5) resulted in nanoparticles of 187 ± 0.98 nm and a positive charge, specifically for breast cancer cells, as evaluated in vitro and confirmed in vivo in a chemically induced tumor model. The gene discussed is TNFRSF10B; the disease is breast cancer.